Summary Background
A multidrug resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambodia c.2008-2013, causing high treatment failure rates to the frontline combination therapy dihydroartemisinin-piperaquine. Here, we report on the evolution and spread of KEL1/PLA1 in subsequent years.
Methods
We analysed whole genome sequencing data from 1,673 P. falciparum clinical samples collected in 2008-2018 from northeast Thailand, Laos, Cambodia and Vietnam. By investigating genome-wide relatedness between parasites, we inferred patterns of shared ancestry in the KEL1/PLA1 population.
Findings
KEL1/PLA1 spread rapidly from 2015 into all of the surveyed countries and now exceeds 80% of the P. falciparum population in several regions. These parasites maintained a high level of genetic relatedness reflecting their common origin. However, several genetic subgroups have recently emerged within this co-lineage with diverse geographical distributions. Some of these emerging KEL1/PLA1 subgroups carry recent mutations in the chloroquine resistance transporter (crt) gene, which arise on a specific genetic background comprising multiple genomic regions.
Research in context
Evidence before this study This study updates our previous work describing the emergence and spread of a multidrug resistant P. falciparum co-lineage (KEL1/PLA1) within Cambodia up to 2013. Since then, a regional genetic surveillance project, GenRe-Mekong, has reported that markers of dihydroartemisinin-piperaquine (DHA-PPQ) resistance have increased in frequency in neighbouring countries. A PubMed search (terms: "artemisinin", "piperaquine", "resistance", "southeast asia") for articles listed since our previous study (from 30/10/2017 to 05/01/2019) yielded 28 results, including reports of a recent sharp decline in DHA-PPQ clinical efficacy in Vietnam; the spread of genetic markers of DHA-PPQ resistance into neighbouring countries by Imwong and colleagues; and multiple reports associating mutations in the crt gene with piperaquine resistance, including newly emerging crt variants in Southeast Asia.
Added value of this study
We analysed P. falciparum whole genomes collected up to early 2018 from Eastern Southeast Asia (Cambodia and surrounding regions), describing the fine-scale epidemiology of multiple KEL1/PLA1 genetic subgroups that have spread out from Cambodia since 2015 and taken over indigenous parasite populations in northeastern Thailand, southern and central Vietnam and parts of southern Laos. Several newly emerging crt mutations accompanied the spread and expansion of KEL1/PLA1 subgroups, suggesting an active proliferation of biologically fit, multidrug resistant parasites.
Introduction
In recent years, frontline treatments for Plasmodium falciparum malaria have been failing in parts of Southeast Asia 1-3 , a historic epicentre for the emergence and spread of antimalarial drug resistance 4 .
The current treatment for P. falciparum consists of a fast-acting artemisinin derivative and a longeracting partner drug, termed artemisinin combination therapy (ACT). Dihydroartemisinin with piperaquine (DHA-PPQ) has been the ACT of choice in Cambodia, Vietnam and Thailand for lengthy periods during the last decade. Around 2008, parasites in western Cambodia began developing DHA-PPQ resistance, manifest first through delayed clearance in response to artemisinins (now widespread in Southeast Asia [5] [6] [7] [8] [9] ), and later with the addition of resistance to the partner drug piperaquine 1, 3, 8 . By 2013, DHA-PPQ failed to clear P. falciparum infections in 46% of patients treated in western Cambodia 3 . This arose on a background of extensive pre-existing resistance to multiple antimalarials, leaving limited treatment options and threatening the future of malaria control and elimination in the region.
Large-scale genetic analyses have revealed the detailed epidemiology of drug resistance [10] [11] [12] [13] [14] [15] , complementing the clinical observation of increasing rates of treatment failure. Non-synonymous mutations in kelch13 -the most prevalent of which is the C580Y mutation 9, 11, 16 -and amplification of plasmepsin-II and plasmepsin-III [17] [18] [19] [20] have proved valuable markers for tracking artemisinin and piperaquine resistance, respectively. These genetic markers increased in frequency across the eastern part of the Greater Mekong Subregion from 2008 to 2015 [12] [13] [14] [15] , corresponding with the spread of DHA-PPQ treatment failure. Whole genome sequencing has provided an even deeper insight into the movement, demographics and evolution of parasites, addressing questions about the origins and mechanisms of spread of these mutations 12, 13 . In 2018, detailed analyses of a large whole genome dataset, including samples up to 2013, revealed that most parasites with the kelch13 C580Y mutation and the plasmepsin-II/III amplification were derived from a single parasite colineage, termed KEL1/PLA1, that arose in western Cambodia 13 .
Such analyses raised several key uncertainties surrounding the future of KEL1/PLA1. Would these parasites continue their aggressive spread out from Cambodia? Would they spread clonally or heterogeneously? Could they evolve even higher levels of drug resistance or increased fitness? Recently, it was reported that newly emerging mutations in the chloroquine resistance transporter (crt) gene caused piperaquine resistance in vitro [21] [22] [23] . These crt substitutions occurred on a plasmepsin-II/III amplified genetic background, raising the question of how mutations at multiple loci interact to yield DHA-PPQ resistant phenotypes; where and by what process the new crt mutations are spreading; and how these mutations relate to the evolution and expansion of the KEL1/PLA1 colineage. To address these questions, we investigated the genomic epidemiology of DHA-PPQ resistant parasites using the most recent P. falciparum genomic dataset currently available, including samples up to early 2018, collected across the region through the MalariaGEN P. falciparum Community Project.
Results
Extensive international expansion and invasion of genetically related drug resistant parasites Figure 2) . The tendency for KEL1 to co-occur with PLA1 increased significantly from 2007-2011 to 2016-2018 (r 2 0.28 vs 0.41, respectively), and the majority of parasites sampled in later years were KEL1/PLA1 (354/695, 51%), reflecting the continued expansion of this co-lineage ( Figure 1A ). Before 2009, KEL1/PLA1 was only found in western Cambodia; by 2016-2018 its prevalence had risen to >50% in all regions sampled except Laos ( Figure 1B ). This rapid rise was particularly dramatic in northeast Thailand and Vietnam, where over 80% of recent samples were KEL1/PLA1, despite their absence from these areas just eight years earlier. This is consistent with near-wholescale replacement of indigenous parasite populations with KEL1/PLA1 in these areas.
In previous work, we demonstrated that KEL1/PLA1 parasites from northeast Cambodia were genetically similar to those from western Cambodia, consistent with direct spread from western to northeast Cambodia 13 . We extended this analysis by examining the pattern of genetic similarity between parasites across the entire ESEA region. Overall, KEL1/PLA1 parasites had lower genetic diversity than non-KEL1/PLA1 parasites (median = 0.032 and 0.073, respectively; P<10 . This is consistent with the view that KEL1/PLA1 is an invading population of western Cambodian origins spreading into surrounding countries.
Diversity within the KEL1/PLA1 family
Given the high degree of genetic similarity between KEL1/PLA1 parasites, we investigated whether they have spread through a single clonal expansion or as multiple independent subgroups. Hierarchical clustering of pairwise genetic distances was used to identify groups of more closely related KEL1/PLA1 parasites ( Figure 3 ). We defined subgroups of related parasites as those whose pairwise genetic distance was in the lower quartile of the KEL1/PLA1 population (Supplementary Table 2 ).
Subgroups 1 (n= 84), 2 (n= 79) and 3 (n= 47) mostly emerged since 2016 and were all present in Cambodia, Vietnam and Laos ( Figure 4A -B). Of note, these larger KEL1/PLA1 subgroups were not geographically restricted and co-existed simultaneously in the same locations across ESEA. This combination of high genetic similarity and broad geographic dispersal over just a few years implies rapid proliferation and expansion in independent overlapping transmission waves, suggesting they possess a selective advantage. In contrast, subgroup 4 (n=36) and subgroup 6 (n=19) were largely confined to Cambodia; these subgroups were responsible for the initial KEL1/PLA1 expansion in 2007-2011, but subsequently became uncommon. We also identified smaller subgroups with limited geographic and temporal distributions, such as subgroup 5 (n=24) which was almost exclusively found in northeast Cambodia in 2016-2017.
Emerging CRT mutations associated with KEL1/PLA1 subgroup expansions
The recent, rapid international expansion of some KEL1/PLA1 subgroups after several years of confinement in Cambodia raises the question of whether new genetic changes have produced advantageous phenotypic effects in these subgroups. One candidate set of driver mutations are substitutions in the crt gene (PF3D7_0709000) that were recently associated with piperaquine resistance 22 . To investigate this possibility, we calculated the changes in allele frequency in ESEA for all non-synonymous crt SNPs from earlier sampling years (2007-2011) to later years (2016-2018) (Supplementary Table 3 ). Three of these mutations (T93S, F145I and I218F), here referred to as Newly Emerging Alleles (NEAs), were rare in 2007-2011 (frequency ≤1%) and rose in frequency by >5% by 2016-2018 (24%, 7% and 13% of all ESEA samples, respectively). These mutations were mutually exclusive: in the entire analysis dataset, we did not identify any sample with multiple NEAs, despite their being present in the same geographic regions in the same time periods.
We found that NEAs occurred on top of a specific constellation of other, more prevalent crt mutations (Supplementary Figure 8) . First, this background comprised K76T and several other crt mutations in common with all chloroquine resistant (CQ-R) parasites 24 . Second, NEAs were only found on the main CQ-R haplotype in ESEA, denoted CVIET (named by crt amino acid positions 72-76). Third, they occurred mainly on top of crt mutations N326S and I356T, which have previously been associated with artemisinin resistant kelch13 variants 11 . Finally, NEAs were mainly (though not exclusively) found in KEL1/PLA1 parasites. Four other mutually exclusive crt alleles found at lower frequencies than the NEAs (H97Y, H97L, M343I and G353V) were also associated with the same genetic background, with the exception of H97L, which occurred only in non-PLA1 parasites. Consistent with the spread of KEL1/PLA1 and rising frequency of NEAs, SNPs associated with the CVIET haplotype have all increased in frequency over the study period at the expense of those in other crt haplotypes (Supplementary Table 3 ).
NEAs were embedded within long shared haplotypes, with reduced genetic diversity across the whole of chromosome 7 ( Supplementary Figures 9-11 ). This denotes limited breakdown through recombination, typical of a very recent selective sweep. Consistent with their recent origin, NEAs were mainly found in newer KEL1/PLA1 outbreak subgroups: T93S and F145I were almost at fixation in subgroups 1 and 3, respectively, while subgroup 2 contained a mixture of T93S and I218F parasites ( Figure 4C, Supplementary Figure 6 ). In summary, our data suggest that multiple KEL1/PLA1 genetic subgroups were able to spread rapidly across borders in separate transmission waves following the acquisition of one of several mutually exclusive crt mutations, which have emerged on a complex genetic background comprising a constellation of other crt mutations that have accumulated over decades in ESEA.
Northeast Thailand provides a case study in the genomic epidemiology of these spreading multidrug resistant parasites. In 2011, all sampled parasites from northeast Thailand were kelch13 R539T mutants, and possessed neither the plasmepsin-II/III amplification nor any NEAs. Although they had delayed parasite clearance times 9, 11, 16 , they were sensitive to piperaquine, such that DHA-PPQ remained an effective treatment. These parasites had exceptionally low genetic diversity (Supplementary Figure 3) , perhaps reflecting population collapse due to effective malaria control efforts. By 2017, however, KEL1/PLA1 had entirely replaced the previous R539T population, with a corresponding rise in DHA-PPQ resistance and treatment failure rates. While the majority of these parasites were from subgroup 3 and possessed the crt F145I mutation, we found other NEAs in this area, suggesting that multiple "enhanced" KEL1/PLA1 subgroups, possessing distinct and mutually exclusive crt mutations, have independently invaded northeast Thailand, replacing earlier parasite populations.
Discussion
After a decade of progress 25 13 . Here, we describe the ongoing evolution and expansion of multidrug resistant P. falciparum using whole genomes sampled across ESEA collected up to early 2018.
Our data clearly demonstrate that KEL1/PLA1 has continued its spread out from western Cambodia and is now highly prevalent in multiple regions including northeast Thailand, Vietnam and south Laos, where it has frequently replaced previous indigenous populations. Regardless of the sampling location, KEL1/PLA1 parasites were genetically distinct from non-KEL1/PLA1 parasites, reflecting their recent shared ancestry from western Cambodia. The genomic data show that underlying this spread is not a single lineage but multiple subgroups of KEL1/PLA1 parasites, which have spread widely across ESEA in independent transmission waves. These recently expanding subgroups carry newly emerging alleles (NEAs) in the crt gene, which have arisen on a specific constellation of background crt mutations and most frequently in KEL1/PLA1 parasites. The rapid rise in frequency of these crt alleles suggests that they are markers of an advantageous phenotype. One NEA (F145I) has been shown to reduce piperaquine sensitivity in vitro 22 , and a new clinical study (van der Pluijm et al.
in this issue) demonstrates that NEAs are associated with a higher rate of DHA-PPQ treatment failures. Other crt alleles arising on a similar genetic background may also be functionally significant -G353V and H97Y have been associated with reduced piperaquine sensitivity in vitro 22 and H97Y
with increased DHA-PPQ treatment failures (van der Pluijm et al.). Thus, several novel crt variants may be capable of reducing parasite sensitivity to piperaquine, and among these the three NEAs are the alleles whose recent rise in frequency is most conspicuous in our dataset.
KEL1/PLA1 parasites emerged in western Cambodia and expanded within Cambodia during an initial phase starting around 2008. They progressively replaced the local parasite population, such that by 2014 nearly all parasites sampled from western Cambodia were KEL1/PLA1. 13 This was likely driven by DHA-PPQ resistance, consistent with the association found between plasmepsin-II/III amplification and piperaquine resistance in parasites collected before NEAs were found at significant frequencies 17, 18 . After several years of continued exposure to DHA-PPQ, Cambodian parasites acquired further mutations, notably in the crt gene, and this may have produced an enhanced phenotype conferring higher-level DHA-PPQ resistance. KEL1/PLA1 subgroups possessing these crt mutations were then able to spread rapidly into surrounding regions in the 2015-2018 period.
These findings illustrate an evolutionary process in action. Artemisinin resistance first began as delayed parasite clearance caused by many mutually exclusive kelch13 mutations, which were generally at low frequency and restricted in geographic range. Over time, a single kelch13 mutation (C580Y) has become dominant in ESEA, in association with several mutations such as variants in ferredoxin, arps10, mdr2 and crt 11, 12 . Thus, a soft sweep (many different, independently emerging advantageous kelch13 mutations) turned into a hard sweep of the kelch13 C580Y variant as the KEL1/PLA1 co-lineage, resistant to both artemisinin and piperaquine, rose in frequency and swept through Cambodia 13 and beyond. Following that harder sweep, the parasites have diversified into separate evolutionary branches with emerging new properties. This perhaps reflects a general tendency for diversification after a hard sweep, as the population "explores" a vast evolutionary space and acquires new mutations. The genetic background that has accumulated in ESEA appears to underpin the emergence of crt NEAs, as multiple alleles have arisen independently within the last few years that are absent elsewhere. It remains to be seen whether one of these NEAs will becomes dominant and drive a new hard sweep, as kelch13 C580Y did.
The spread of KEL1/PLA1 up to 2013 described by Amato et al. 13 has worsened significantly. By analogy with cancer biology, KEL1/PLA1 can be viewed as an aggressive cell line that, since 2013, has metastasised, invading new territories and acquiring new genetic properties. This emphasises the importance of surveillance systems in guiding and accelerating malaria elimination. It is possible that prolonged use of DHA-PPQ in Cambodia after resistance to these agents first emerged created the selective pressure for the evolution of enhanced KEL1/PLA1 subgroups. To support national malaria control programmes in their decisions on first-line therapies, particularly given the spread and intensification of resistance, requires genetic surveillance and effective translation of its results. It is with this intent that a large number of the recent samples analysed in this study, particularly from Vietnam, Laos and Cambodia, were contributed by national malaria control programmes collaborating with GenRe-Mekong, a genetic surveillance project operating across the Greater Mekong Subregion. It is hoped that such surveillance tools will support effective elimination of highly drug resistant P. falciparum from the Greater Mekong sub-region, and control and elimination efforts elsewhere.
Materials and Methods

P. falciparum whole genome sequence data
We analysed whole genome sequence data from samples included in the MalariaGEN P. falciparum Community Project (https://www.malariagen.net/projects/p-falciparum-community-project) Pf6.2 data release. A large proportion of the samples were collected in clinical observational or drug efficacy studies as detailed in previous publications 1, 9, 12, 13 . Recently collected, previously unpublished samples were contributed by two large-scale multi-site projects: the Tracking Artemisinin Resistance Collaboration II (TRAC2), and the Genetic Reconnaissance in the Greater Mekong Subregion project (GenRe-Mekong, https://www.malariagen.net/projects/spotmalaria). The TRAC2 study (see van de Pluijm et al. in this issue) conducted detailed clinical drug efficacy trials at seven sites in the ESEA region, contributing DNA from both dried blood spots (DBS) and leukocyte-depleted venous blood samples. Up to 120 symptomatic patients per site were enrolled, all of whom provided written informed consent under protocols approved by the relevant local ethics authorities and by the Oxford Tropical Research Ethics Committee (OxTREC), Oxford, UK. The GenRe-Mekong project contributed samples from three genetic surveillance projects in partnership with malaria control programmes in Vietnam (IMPE-QN: Institute of Malariology, Parasitology and Entomology Quy Nhon), Lao PDR (CMPE: Centre of Malariology, Parasitology, and Entomology) and Cambodia (Center for Parasitology, Entomology, and Malaria Control). DBS samples were collected from RDT-positive symptomatic patients on admission at provincial hospitals and district health centres in multiple provinces of each country (Supplementary Table 1 ). All patients provided informed consent (oral in the Lao PDR, written in Vietnam and Cambodia) under protocols approved by the relevant local ethics authorities and OxTREC. These surveillance projects did not involve any clinical component, and no clinical or personal patient data were used in this analysis. The MalariaGEN Analytics website (www.malariagen.net/analytics) provides further details on participating studies and field sites, sample processing and whole genome sequencing approach.
Whole genome sequencing and dataset selection DNA from DBS samples underwent selective whole genome amplification 28 prior to sequencing.
Sequence data were generated at the Wellcome Sanger Institute with Illumina short-read technology, and read counts for genotyped variants were called with a standardised analysis pipeline 29 . Samples were genotyped at 1,043,334 biallelic SNPs in the nuclear genome, which were discovered and quality-filtered in the Pf6.0 release (manuscript under preparation). Genotypes were called only with a coverage ≥5 reads, and alleles were disregarded when represented by fewer than 2 reads, or 5% of reads when coverage was >50.
To minimize errors and biases, we excluded from analysis all known or suspected duplicate samples, samples from time sequences and from recurrences, samples sequenced with reads <75 nucleotides, and those that had insufficient coverage at >25% of the SNPs. We removed all SNPs that either were invariant or had insufficient coverage in >25% of the remaining samples, leaving 56,026 SNPs to be used in our analysis. We used genotypes at these SNPs to estimate FWS as previously described 29 ,
and removed samples with FWS<0.95, yielding a final set of 1,673 essentially monoclonal samples to be analysed.
KEL1, PLA1 and crt haplotype classification
To identify mutations in the P falciparum kelch13 gene, we scanned all sequencing reads that align to amino acid positions >350 in this gene, listing any nonsynonymous variants found. Samples where no nonsynonymous mutations were found were listed were labelled as wild-type, unless >25% of position had insufficient coverage for genotyping, in which case the sample was labelled as undetermined for kelch13. The remaining samples were labelled according to the kelch13 mutation found, or as heterozygous if the mutation site was heterozygous, or if more than one nonsynonymous variant was found in the sample. For our analysis of C580Y mutants, we only selected samples labelled for that mutation, disregarding heterozygous samples as these may contain a proportion of non-C580Y parasites.
To assign membership to the KEL1 lineage, we tested the five SNPs characteristic of this haplotype 13 .
Moving away from the kelch13 gene and ignoring missing genotypes, we counted how many of these positions carried a KEL1 characteristic allele, before encountering a position with the other allele. Samples with a total of three or more characteristic allele were labelled as KEL1. PLA1 parasites were identified by scanned all sequencing reads for the characteristic duplication breakpoint 13 . The crt haplotypes were determined from the genotypes at the positions that characterize the haplotypes (see Results). A sample was assigned a given haplotype if the corresponding position was mutated while the remaining five had wild type alleles (with the exception of the crt218F characteristic position, which has relatively high missingness and was ignored when missing in the presence of another characteristic mutation). The remaining samples were assigned to the "no crt" group if all six positions were found to be wild-type, and "missing" if the genotype could not be called at all the mutations.
Population Structure Analysis
Analyses were performed using a combination of custom software programs written in Java, R and Python using the toolkit Scikit-Allel (https://scikit-allel.readthedocs.io/en/latest/). To study population structure, we constructed an NxN pairwise distance matrix, where N is the number of samples, using a previously published procedure 12 . Analyses of relatedness were conducted using the R language, and specifically the hclust hierarchical clustering function and the cmdscale implementation of the Classical Multidimensional Scaling method for PCoA.
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